GLP-1 drugs could reduce long-term sick leave: Study
The heartbeat of a veteran entrepreneur is forged in discipline, adaptability, and the stubborn resilience that follows long years of service. When a study from Danish data points to a 17% reduction in long-term absences for those taking GLP-1 therapies, the news doesn’t just whisper about medical innovation. It sounds a clarion call to a community for whom every absence could mean a missed contract, delayed launch, or the erosion of the hard-won reputation built through gritty, unglamorous days of bootstrapped growth. GLP-1 drugs, at their core, support metabolic regulation and offer potential improvements in energy levels, focus, and overall stamina for patients dealing with chronic conditions like type 2 diabetes. For veteran entrepreneurs, the implication is less about a medical prescription and more about a strategic lens: sustained health as an economic asset. If a founder can maintain steadier attendance, fewer disruptions, and steadier cognitive function through improved met...